1. Lessons learnt from presence of N-nitrosamine impurities in sartan;medicines [Internet],2020
2. The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny;Nudelman;Org Process Res Dev,2023
3. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals;Schlingemann;J Pharm Sci,2023
4. Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in;human medicinal products,2024
5. FDA. Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs) Guidance for Industry. 2023.